# EDGAR Filing Document

**Accession Number:** 0001761055
**File Stem:** 0001752724-25-157926
**Filing Date:** 2025-6
**Character Count:** 59300
**Document Hash:** 45eb89d77f8b5283911e9591d8c4c97b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-25-157926.hdr.sgml**: 20250626

**ACCESSION NUMBER**: 0001752724-25-157926

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250430

**FILED AS OF DATE**: 20250626

**DATE AS OF CHANGE**: 20250626

**PERIOD START**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BlackRock ETF Trust
- **CENTRAL INDEX KEY:** 0001761055

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23402
- **FILM NUMBER:** 251076997

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809
- **BUSINESS PHONE:** 8004417762

**MAIL ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809

## Series and Classes Contracts Data

### iShares Health Innovation Active ETF (Series ID: S000069260)

| Class ID   | Class Name                           | Ticker Symbol   |
|:---|:---|:---|
| C000221226 | iShares Health Innovation Active ETF |  |

## Nport-Ex

April 30, 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

2025 Quarterly Report <br>&nbsp;&nbsp;&nbsp;&nbsp;(Unaudited)<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| |
|:---|
| **BlackRock ETF Trust** |
| • iShares Health Innovation Active ETF \| BMED \| NYSE Arca |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Not FDIC Insured • May Lose Value • No Bank Guarantee**<br>

------

Schedule of Investments (unaudited)

April 30, 2025

**iShares Health Innovation Active ETF**

**(Formerly BlackRock Future Health ETF)**

**(Percentages shown are based on Net Assets)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Common Stocks** | **Common Stocks** | **Common Stocks** |
| **Biotechnology — 35.4%** | **Biotechnology — 35.4%** | **Biotechnology — 35.4%** |
| 4D Molecular Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 177 | $596 |
| AbbVie Inc. | &nbsp;&nbsp;&nbsp; 420 | 81942 |
| AC Immune SA<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 350 | 606 |
| Alkermes PLC<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 522 | 15018 |
| Allogene Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1179 | 1981 |
| Alnylam Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 146 | 38433 |
| Amgen Inc. | &nbsp;&nbsp;&nbsp; 158 | 45965 |
| Arcellx Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 211 | 13704 |
| Arcus Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 272 | 2380 |
| Argenx SE, ADR<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 172 | 110964 |
| Arrowhead Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 127 | 1764 |
| Ascendis Pharma A/S, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 84 | 14317 |
| Autolus Therapeutics PLC , ADR<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1221 | 1722 |
| Beam Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 305 | 6079 |
| BeiGene Ltd., ADR<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 170 | 44168 |
| Bicycle Therapeutics PLC, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 147 | 1258 |
| Biogen Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 168 | 20341 |
| Biohaven Ltd., NVS<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 124 | 2743 |
| BioNTech SE, ADR<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 47 | 4895 |
| Blueprint Medicines Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 83 | 7429 |
| Bridgebio Pharma Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 552 | 21175 |
| Denali Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 546 | 9091 |
| Disc Medicine Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 79 | 3904 |
| Dyne Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 330 | 3891 |
| Exact Sciences Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 907 | 41395 |
| Exelixis Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1234 | 48311 |
| Genmab A/S<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 125 | 26505 |
| Gilead Sciences Inc. | &nbsp;&nbsp;&nbsp; 644 | 68612 |
| Halozyme Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 690 | 42380 |
| Insmed Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 333 | 23976 |
| Ionis Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 250 | 7677 |
| Merus NV<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 160 | 7282 |
| Metsera Inc., NVS<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 321 | 7739 |
| Moderna Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 325 | 9275 |
| MoonLake Immunotherapeutics, Class A, NVS<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 55 | 2314 |
| Natera Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 336 | 50712 |
| Neurocrine Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 353 | 38015 |
| Nuvalent Inc., Class A<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 211 | 16194 |
| ORIC Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 392 | 2238 |
| Protagonist Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 134 | 6140 |
| Prothena Corp. PLC<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 235 | 2162 |
| PTC Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 426 | 21232 |
| REGENXBIO Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 306 | 2941 |
| Revolution Medicines Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 191 | 7713 |
| Rhythm Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 660 | 43025 |
| Roivant Sciences Ltd.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1578 | 18336 |
| Spyre Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 53 | 807 |
| Stoke Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 879 | 8579 |
| Summit Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 90 | 2171 |
| TScan Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1676 | 2690 |
| Twist Bioscience Corp.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 214 | 8200 |
| United Therapeutics Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 75 | 22732 |
| Vigil Neuroscience Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 363 | 762 |
| Viking Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 70 | 2021 |
| Vir Biotechnology Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 340 | 2081 |
| Voyager Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 585 | 2083 |
| Xenon Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 448 | 17114 |
| Zealand Pharma A/S<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 188 | 13297 |
|  |  | 1031077 |

---

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Health Care Equipment & Supplies — 24.9%** | **Health Care Equipment & Supplies — 24.9%** | **Health Care Equipment & Supplies — 24.9%** |
| Abbott Laboratories | &nbsp;&nbsp;&nbsp; 824 | $107738 |
| Abiomed Inc., CVR<sup>(c)</sup> | &nbsp;&nbsp;&nbsp; 246 | 544 |
| Alcon AG | &nbsp;&nbsp;&nbsp; 225 | 21962 |
| Becton Dickinson & Co. | &nbsp;&nbsp;&nbsp; 69 | 14289 |
| Boston Scientific Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1293 | 133011 |
| Dexcom Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 247 | 17631 |
| Edwards Lifesciences Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1101 | 83114 |
| Glaukos Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 127 | 11970 |
| Hologic Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 554 | 32243 |
| Inspire Medical Systems Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 40 | 6335 |
| Insulet Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 245 | 61811 |
| Intuitive Surgical Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 104 | 53643 |
| Medtronic PLC | &nbsp;&nbsp;&nbsp; 1007 | 85353 |
| Novocure Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 804 | 14585 |
| Nyxoah SA, Class B<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 455 | 2794 |
| Penumbra Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 118 | 34555 |
| Sonova Holding AG, Registered | &nbsp;&nbsp;&nbsp; 63 | 19367 |
| Stryker Corp. | &nbsp;&nbsp;&nbsp; 65 | 24305 |
|  |  | 725250 |
| **Health Care Providers & Services — 8.6%** | **Health Care Providers & Services — 8.6%** | **Health Care Providers & Services — 8.6%** |
| Cencora Inc. | &nbsp;&nbsp;&nbsp; 255 | 74631 |
| CVS Health Corp. | &nbsp;&nbsp;&nbsp; 190 | 12675 |
| Guardant Health Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 882 | 41657 |
| Labcorp Holdings Inc. | &nbsp;&nbsp;&nbsp; 117 | 28198 |
| McKesson Corp. | &nbsp;&nbsp;&nbsp; 100 | 71279 |
| Quest Diagnostics Inc. | &nbsp;&nbsp;&nbsp; 125 | 22277 |
|  |  | 250717 |
| **Industrial Conglomerates — 0.0%** | **Industrial Conglomerates — 0.0%** | **Industrial Conglomerates — 0.0%** |
| Frequency Therapeutics Inc., NVS<sup>(c)</sup> | &nbsp;&nbsp;&nbsp; 420 |  |
| **Life Sciences Tools & Services — 11.3%** | **Life Sciences Tools & Services — 11.3%** | **Life Sciences Tools & Services — 11.3%** |
| Bio-Techne Corp. | &nbsp;&nbsp;&nbsp; 686 | 34540 |
| Danaher Corp. | &nbsp;&nbsp;&nbsp; 143 | 28504 |
| IQVIA Holdings Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 121 | 18764 |
| Lonza Group AG, Registered | &nbsp;&nbsp;&nbsp; 132 | 94843 |
| QIAGEN NV | &nbsp;&nbsp;&nbsp; 662 | 28301 |
| Repligen Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 390 | 53816 |
| Thermo Fisher Scientific Inc. | &nbsp;&nbsp;&nbsp; 62 | 26598 |
| Waters Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 45 | 15648 |
| West Pharmaceutical Services Inc. | &nbsp;&nbsp;&nbsp; 136 | 28735 |
|  |  | 329749 |
| **Pharmaceuticals — 12.8%** | **Pharmaceuticals — 12.8%** | **Pharmaceuticals — 12.8%** |
| Arvinas Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 390 | 3752 |
| Axsome Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 94 | 10555 |
| Bristol-Myers Squibb Co. | &nbsp;&nbsp;&nbsp; 1087 | 54567 |
| Daiichi Sankyo Co. Ltd. | &nbsp;&nbsp;&nbsp; 400 | 10232 |
| Edgewise Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 352 | 5773 |
| Eli Lilly & Co. | &nbsp;&nbsp;&nbsp; 25 | 22474 |
| Johnson & Johnson | &nbsp;&nbsp;&nbsp; 270 | 42204 |
| Mirati Therapeutics Inc., NVS<sup>(c)</sup> | &nbsp;&nbsp;&nbsp; 334 | 247 |
| Novartis AG, Registered | &nbsp;&nbsp;&nbsp; 255 | 29085 |
| Pfizer Inc. | &nbsp;&nbsp;&nbsp; 1206 | 29439 |
| Roche Holding AG, NVS | &nbsp;&nbsp;&nbsp; 249 | 81420 |
| Structure Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 107 | 2889 |
| Teva Pharmaceutical Industries Ltd., ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 465 | 7212 |
| UCB SA | &nbsp;&nbsp;&nbsp; 396 | 72602 |
| WaVe Life Sciences Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 195 | 1505 |
|  |  | 373956 |
| **Total Common Stocks — 93.0%** <br>**(Cost: $2,667,945)** | **Total Common Stocks — 93.0%** <br>**(Cost: $2,667,945)** | 2710749 |

---

------

Schedule of Investments (unaudited)(continued)

April 30, 2025

**iShares Health Innovation Active ETF**

**(Formerly BlackRock Future Health ETF)**

**(Percentages shown are based on Net Assets)**

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Preferred Stocks** | **Preferred Stocks** | **Preferred Stocks** |
| **Life Sciences Tools & Services — 1.7%** | **Life Sciences Tools & Services — 1.7%** | **Life Sciences Tools & Services — 1.7%** |
| Sartorius AG, Preference Shares, NVS | &nbsp;&nbsp;&nbsp; 194 | $50361 |
| **Total Preferred Stocks — 1.7%** <br>**(Cost: $61,335)** | **Total Preferred Stocks — 1.7%** <br>**(Cost: $61,335)** | 50361 |
| **Total Long-Term Investments — 94.7%** <br>**(Cost: $2,729,280)** | **Total Long-Term Investments — 94.7%** <br>**(Cost: $2,729,280)** | 2761110 |
| **Short-Term Securities** | **Short-Term Securities** | **Short-Term Securities** |
| **Money Market Funds — 11.2%** | **Money Market Funds — 11.2%** | **Money Market Funds — 11.2%** |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency Shares, <br> 4.46%<sup>(d)(e)(f)</sup><br>| &nbsp;&nbsp;&nbsp; 156819 | 156882 |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Treasury, SL Agency Shares, <br> 4.30%<sup>(d)(e)</sup><br>| &nbsp;&nbsp;&nbsp; 170000 | 170000 |
| **Total Short-Term Securities — 11.2%** <br>**(Cost: $326,838)** | **Total Short-Term Securities — 11.2%** <br>**(Cost: $326,838)** | 326882 |
| **Total Investments — 105.9%** <br>**(Cost: $3,056,118)** | **Total Investments — 105.9%** <br>**(Cost: $3,056,118)** | 3087992 |
| **Liabilities in Excess of Other Assets — (5.9)%** | **Liabilities in Excess of Other Assets — (5.9)%** | (172575)<br>|
| **Net Assets — 100.0%** | **Net Assets — 100.0%** | $2915417 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> All or a portion of this security is on loan.

<sup>(c)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. 

<sup>(d)</sup> Affiliate of the Fund.

<sup>(e)</sup> Annualized 7-day yield as of period end.

<sup>(f)</sup> All or a portion of this security was purchased with the cash collateral from loaned securities. 

**Affiliates**

Investments in issuers considered to be affiliate(s) of the Fund during the period ended April 30, 2025 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *Affiliated Issuer* | *Value at* <br>*07/31/24*<br>| *Purchases* <br>*at Cost*<br>| &nbsp;&nbsp; *Net Realized* <br>*Gain (Loss)*<br>| *Change in* <br>*Unrealized* <br>*Appreciation* <br>*(Depreciation)*<br>| *Value at* <br>*04/30/25*<br>| *Shares* <br>*Held at* <br>*04/30/25*<br>| *Income* | &nbsp;&nbsp; *Capital* <br>*Gain* <br>*Distributions* <br>*from* <br>*Underlying* <br>*Funds*<br>|
| BlackRock Cash Funds: Institutional, SL Agency Shares | $286285 | $—<br> $(129389 )<sup>(a)</sup><br>| $20 | $(34)<br>| $156882 | 156819 | $926 <br><sup>(b)</sup><br>| $— |
| BlackRock Cash Funds: Treasury, SL Agency Shares | &nbsp;&nbsp; 270000 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; —<br> (100000 )<sup>(a)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp; 170000 | 170000 | &nbsp;&nbsp; 5432 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — |
|  |  |  | $20 | $(34) | $326882 |  | $6358 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Represents net amount purchased (sold).

<sup>(b)</sup> All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and other payments to and from borrowers of securities. 

**Fair Value Hierarchy as of Period End** 

Various inputs are used in determining the fair value of financial instruments at the measurement date. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

• Level 1 – Unadjusted price quotations in active markets/exchanges that the Fund has the ability to access for identical assets or liabilities;

• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 – Inputs that are unobservable and significant to the entire fair value measurement for the asset or liability (including the Valuation Committee's assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based

------

Schedule of Investments (unaudited)(continued)

April 30, 2025

**iShares Health Innovation Active ETF**

**(Formerly BlackRock Future Health ETF)**

**Fair Value Hierarchy as of Period End (continued)**

on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Fund's policy regarding valuation of financial instruments, refer to its most recent financial statements.

The following table summarizes the Fund's financial instruments categorized in the fair value hierarchy. The breakdown of the Fund's financial instruments into major categories is disclosed in the Schedule of Investments above.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Level 1* | *Level 2* | *Level 3* | *Total* |
| Assets  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-Term Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stocks | &nbsp;&nbsp; $2362607 | &nbsp;&nbsp; $347351 | &nbsp;&nbsp; $791 | &nbsp;&nbsp; $2710749 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred Stocks | &nbsp;&nbsp; — | &nbsp;&nbsp; 50361 | &nbsp;&nbsp; — | &nbsp;&nbsp; 50361 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-Term Securities  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Money Market Funds | &nbsp;&nbsp; 326882 | &nbsp;&nbsp; — | &nbsp;&nbsp; — | &nbsp;&nbsp; 326882 |
|  | &nbsp;&nbsp; $2689489 | &nbsp;&nbsp; $397712 | &nbsp;&nbsp; $791 | &nbsp;&nbsp; $3087992 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Portfolio Abbreviation** | **Portfolio Abbreviation** |
| ADR | American Depositary Receipt |
| NVS | Non-Voting Shares |

---

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** BlackRock ETF Trust

- **b. Investment Company Act file number:** 811-23402

- **c. CIK number of Registrant:** 0001761055

- **d. LEI of Registrant:** 5493007WBHAKV9JVS642

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 100 BELLEVUE PARKWAY

  - **City:** WILMINGTON

  - **State:** DE

  - **Foreign country:** US

  - **Zip / Postal Code:** 19809

  - **Telephone number:** 800-441-7762

**Item A.2. Information about the Series.**

- **a. Name of Series:** iShares Health Innovation Active ETF

- **b. EDGAR series identifier (if any):** S000069260

- **c. LEI of Series:** 549300QSHQQEGUGOU050

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2025-07-31

- **b. Date as of which information is reported:** 2025-04-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $3212536.85

**Total Liabilities:** $297331.22

**Net Assets:** $2915205.63

**Cash Not Reported:** $9721.60

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000221226 | -3.39%               | -5.85%               | 0.25%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-6829.49                | $-100478.33                                |
| Month 2  | $-14417.76               | $-169227.59                                |
| Month 3  | $-30112.90               | $36687.94                                  |

**Designated Index Information**

- **Index Name:** STOXX GLOBAL BREAKTHROUGH HEALTHCARE

- **Index Identifier:** STFSHIUN

### Schedule of Portfolio Investments

| Name                                           | Title                                                 | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Ionis Pharmaceuticals Inc                      | Ionis Pharmaceuticals Inc                             | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |       250 | NS      | $7677.50      | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| TScan Therapeutics Inc                         | TScan Therapeutics Inc                                | CUSIP: 89854M101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1676 | NS      | $2689.98      | 0.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Arrowhead Pharmaceuticals Inc                  | Arrowhead Pharmaceuticals Inc                         | CUSIP: 04280A100<br>LEI: 549300O3CSB8T7OZ3D66 | Long             | EC               | CORP              | US        |       127 | NS      | $1764.03      | 0.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Protagonist Therapeutics Inc                   | Protagonist Therapeutics Inc                          | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       134 | NS      | $6139.88      | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals Inc                     | Rhythm Pharmaceuticals Inc                            | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |       660 | NS      | $43025.40     | 1.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc                    | Alnylam Pharmaceuticals Inc                           | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |       146 | NS      | $38433.04     | 1.32%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                                    | BioNTech SE                                           | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |        47 | NS      | $4895.05      | 0.17%             |  |  |  | No            |                  1 | On Loan: —       |
| Johnson & Johnson                              | Johnson & Johnson                                     | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |       270 | NS      | $42203.70     | 1.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Exact Sciences Corp                            | Exact Sciences Corp                                   | CUSIP: 30063P105<br>LEI: 549300VM3X1FYD4N9Z14 | Long             | EC               | CORP              | US        |       907 | NS      | $41395.48     | 1.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Repligen Corp                                  | Repligen Corp                                         | CUSIP: 759916109<br>LEI: 54930006QJ0T5AUO1E71 | Long             | EC               | CORP              | US        |       390 | NS      | $53816.10     | 1.85%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA MIRATI THERAPEU                         | CONTRA MIRATI THERAPEU                                | CUSIP: 604CVR027<br>LEI: 529900GYRW59IDQV6N54 | Long             |  | CORP              | US        |       334 | NS      | $247.16       | 0.01%             |  |  |  | No            |                  3 | On Loan: No      |
| CONTRA FREQUENCY THERA                         | CONTRA FREQUENCY THERA                                | CUSIP: 358CVR025<br>LEI: N/A                  | Long             |  | CORP              | US        |       420 | NS      | $0.00         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Merus NV                                       | Merus NV                                              | CUSIP: 000000000<br>LEI: 549300W8GPUWU8QNU293 | Long             | EC               | CORP              | NL        |       160 | NS      | $7281.60      | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                                     | AbbVie Inc                                            | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |       420 | NS      | $81942.00     | 2.81%             |  |  |  | No            |                  1 | On Loan: No      |
| Sonova Holding AG                              | Sonova Holding AG                                     | CUSIP: 000000000<br>LEI: 5299004A0QNX7FBNHS61 | Long             | EC               | CORP              | CH        |        63 | NS      | $19367.08     | 0.66%             |  |  |  | No            |                  2 | On Loan: No      |
| Thermo Fisher Scientific Inc                   | Thermo Fisher Scientific Inc                          | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |        62 | NS      | $26598.00     | 0.91%             |  |  |  | No            |                  1 | On Loan: No      |
| Dyne Therapeutics Inc                          | Dyne Therapeutics Inc                                 | CUSIP: 26818M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       330 | NS      | $3890.70      | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Nyxoah SA                                      | Nyxoah SA                                             | CUSIP: 000000000<br>LEI: 5493002O1ESKZ18OXR80 | Long             | EC               | CORP              | BE        |       455 | NS      | $2793.70      | 0.10%             |  |  |  | No            |                  1 | On Loan: —       |
| Spyre Therapeutics Inc                         | Spyre Therapeutics Inc                                | CUSIP: 00773J202<br>LEI: 52990017AIJPRH3HQH40 | Long             | EC               | CORP              | US        |        53 | NS      | $807.19       | 0.03%             |  |  |  | No            |                  1 | On Loan: —       |
| Beam Therapeutics Inc                          | Beam Therapeutics Inc                                 | CUSIP: 07373V105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       305 | NS      | $6078.65      | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Alcon AG                                       | Alcon AG                                              | CUSIP: 000000000<br>LEI: 549300LDT5AP8S0NBM78 | Long             | EC               | CORP              | CH        |       225 | NS      | $21962.25     | 0.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Novocure Ltd                                   | Novocure Ltd                                          | CUSIP: 000000000<br>LEI: 213800YPP55UMHWA4826 | Long             | EC               | CORP              | JE        |       804 | NS      | $14584.56     | 0.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                                  | Medtronic PLC                                         | CUSIP: 000000000<br>LEI: 549300GX3ZBSQWUXY261 | Long             | EC               | CORP              | IE        |      1007 | NS      | $85353.32     | 2.93%             |  |  |  | No            |                  1 | On Loan: No      |
| Zealand Pharma A/S                             | Zealand Pharma A/S                                    | CUSIP: 000000000<br>LEI: 549300ITBB1ULBL4CZ12 | Long             | EC               | CORP              | DK        |       188 | NS      | $13296.51     | 0.46%             |  |  |  | No            |                  2 | On Loan: No      |
| Genmab A/S                                     | Genmab A/S                                            | CUSIP: 000000000<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |       125 | NS      | $26504.83     | 0.91%             |  |  |  | No            |                  2 | On Loan: No      |
| Roche Holding AG                               | Roche Holding AG                                      | CUSIP: 000000000<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |       249 | NS      | $81419.60     | 2.79%             |  |  |  | No            |                  2 | On Loan: No      |
| Ascendis Pharma A/S                            | Ascendis Pharma A/S                                   | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |        84 | NS      | $14316.96     | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Halozyme Therapeutics Inc                      | Halozyme Therapeutics Inc                             | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |       690 | NS      | $42379.80     | 1.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp                         | Boston Scientific Corp                                | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |      1293 | NS      | $133010.91    | 4.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc                                     | Biogen Inc                                            | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |       168 | NS      | $20341.44     | 0.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Inspire Medical Systems Inc                    | Inspire Medical Systems Inc                           | CUSIP: 457730109<br>LEI: 549300XQQCQ7HCJKTW25 | Long             | EC               | CORP              | US        |        40 | NS      | $6335.20      | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA ABIOMED INC                             | CONTRA ABIOMED INC                                    | CUSIP: 003CVR016<br>LEI: N/A                  | Long             |  | CORP              | US        |       246 | NS      | $543.66       | 0.02%             |  |  |  | No            |                  3 | On Loan: No      |
| Daiichi Sankyo Co Ltd                          | Daiichi Sankyo Co Ltd                                 | CUSIP: 000000000<br>LEI: 353800XGIU2IHQGC9504 | Long             | EC               | CORP              | JP        |       400 | NS      | $10232.24     | 0.35%             |  |  |  | No            |                  2 | On Loan: No      |
| United Therapeutics Corp                       | United Therapeutics Corp                              | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |        75 | NS      | $22731.75     | 0.78%             |  |  |  | No            |                  1 | On Loan: No      |
| BlackRock Funds III                            | BlackRock Cash Funds: Institutional, SL Agency Shares | CUSIP: 066922519<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |    147976 | NS      | $148035.11    | 5.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Sartorius AG                                   | Sartorius AG                                          | CUSIP: 000000000<br>LEI: 529900EQV2DY4FOAMU38 | Long             | EP               | CORP              | DE        |       194 | NS      | $50361.33     | 1.73%             |  |  |  | No            |                  2 | On Loan: No      |
| Insulet Corp                                   | Insulet Corp                                          | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |       245 | NS      | $61811.05     | 2.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Viking Therapeutics Inc                        | Viking Therapeutics Inc                               | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |        70 | NS      | $2020.90      | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Becton Dickinson & Co                          | Becton Dickinson & Co                                 | CUSIP: 075887109<br>LEI: ICE2EP6D98PQUILVRZ91 | Long             | EC               | CORP              | US        |        69 | NS      | $14289.21     | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Penumbra Inc                                   | Penumbra Inc                                          | CUSIP: 70975L107<br>LEI: 549300RGE06P3ECANU72 | Long             | EC               | CORP              | US        |       118 | NS      | $34555.12     | 1.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc                       | Revolution Medicines Inc                              | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |       191 | NS      | $7712.58      | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA Holdings Inc                             | IQVIA Holdings Inc                                    | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |       121 | NS      | $18763.47     | 0.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Vigil Neuroscience Inc                         | Vigil Neuroscience Inc                                | CUSIP: 92673K108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       363 | NS      | $762.30       | 0.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Moderna Inc                                    | Moderna Inc                                           | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |       325 | NS      | $9275.50      | 0.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Biohaven Ltd                                   | Biohaven Ltd                                          | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | VG        |       124 | NS      | $2742.88      | 0.09%             |  |  |  | No            |                  1 | On Loan: —       |
| Stryker Corp                                   | Stryker Corp                                          | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |        65 | NS      | $24304.80     | 0.83%             |  |  |  | No            |                  1 | On Loan: No      |
| ORIC Pharmaceuticals Inc                       | ORIC Pharmaceuticals Inc                              | CUSIP: 68622P109<br>LEI: 54930033FJRNEYBW0L25 | Long             | EC               | CORP              | US        |       392 | NS      | $2238.32      | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Structure Therapeutics Inc                     | Structure Therapeutics Inc                            | CUSIP: 86366E106<br>LEI: N/A                  | Long             | EC               | CORP              | KY        |       107 | NS      | $2889.00      | 0.10%             |  |  |  | No            |                  1 | On Loan: —       |
| Twist Bioscience Corp                          | Twist Bioscience Corp                                 | CUSIP: 90184D100<br>LEI: 549300T23BL59LCOH584 | Long             | EC               | CORP              | US        |       214 | NS      | $8200.48      | 0.28%             |  |  |  | No            |                  1 | On Loan: —       |
| Disc Medicine Inc                              | Disc Medicine Inc                                     | CUSIP: 254604101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |        79 | NS      | $3904.18      | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| CVS Health Corp                                | CVS Health Corp                                       | CUSIP: 126650100<br>LEI: 549300EJG376EN5NQE29 | Long             | EC               | CORP              | US        |       190 | NS      | $12674.90     | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Denali Therapeutics Inc                        | Denali Therapeutics Inc                               | CUSIP: 24823R105<br>LEI: 549300ZTQ2HO18L3Q830 | Long             | EC               | CORP              | US        |       546 | NS      | $9090.90      | 0.31%             |  |  |  | No            |                  1 | On Loan: No      |
| MoonLake Immunotherapeutics                    | MoonLake Immunotherapeutics                           | CUSIP: 61559X104<br>LEI: N/A                  | Long             | EC               | CORP              | KY        |        55 | NS      | $2314.40      | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health Inc                            | Guardant Health Inc                                   | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |       882 | NS      | $41656.86     | 1.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics Inc                        | Axsome Therapeutics Inc                               | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |        94 | NS      | $10555.26     | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |
| WaVe Life Sciences Ltd                         | WaVe Life Sciences Ltd                                | CUSIP: 000000000<br>LEI: 54930070006GPKFYZ813 | Long             | EC               | CORP              | SG        |       195 | NS      | $1505.40      | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Intuitive Surgical Inc                         | Intuitive Surgical Inc                                | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |       104 | NS      | $53643.20     | 1.84%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                                      | Amgen Inc                                             | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |       158 | NS      | $45965.36     | 1.58%             |  |  |  | No            |                  1 | On Loan: No      |
| Labcorp Holdings Inc                           | Labcorp Holdings Inc                                  | CUSIP: 504922105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       117 | NS      | $28198.17     | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Autolus Therapeutics PLC                       | Autolus Therapeutics PLC                              | CUSIP: 05280R100<br>LEI: 549300C0KZP8EYROLL02 | Long             | EC               | CORP              | GB        |      1221 | NS      | $1721.61      | 0.06%             |  |  |  | No            |                  1 | On Loan: —       |
| Abbott Laboratories                            | Abbott Laboratories                                   | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |       824 | NS      | $107738.00    | 3.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Blueprint Medicines Corp                       | Blueprint Medicines Corp                              | CUSIP: 09627Y109<br>LEI: 5299004CC60O9T5HVM83 | Long             | EC               | CORP              | US        |        83 | NS      | $7428.50      | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Lonza Group AG                                 | Lonza Group AG                                        | CUSIP: 000000000<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |       132 | NS      | $94843.22     | 3.25%             |  |  |  | No            |                  2 | On Loan: No      |
| Bridgebio Pharma Inc                           | Bridgebio Pharma Inc                                  | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |       552 | NS      | $21174.72     | 0.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Bicycle Therapeutics PLC                       | Bicycle Therapeutics PLC                              | CUSIP: 088786108<br>LEI: 213800XKUI6R7GKC3E43 | Long             | EC               | CORP              | GB        |       147 | NS      | $1258.32      | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Prothena Corp PLC                              | Prothena Corp PLC                                     | CUSIP: 000000000<br>LEI: 5299009ZXQ8NIIJ8OL30 | Long             | EC               | CORP              | IE        |       235 | NS      | $2162.00      | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvalent Inc                                   | Nuvalent Inc                                          | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       211 | NS      | $16194.25     | 0.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Xenon Pharmaceuticals Inc                      | Xenon Pharmaceuticals Inc                             | CUSIP: 98420N105<br>LEI: 549300XV44Q9Z1MIPQ03 | Long             | EC               | CORP              | CA        |       448 | NS      | $17113.60     | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Stoke Therapeutics Inc                         | Stoke Therapeutics Inc                                | CUSIP: 86150R107<br>LEI: 549300RD25SS2DIJHJ67 | Long             | EC               | CORP              | US        |       879 | NS      | $8579.04      | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                                     | Dexcom Inc                                            | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |       247 | NS      | $17630.86     | 0.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcellx Inc                                    | Arcellx Inc                                           | CUSIP: 03940C100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       211 | NS      | $13704.45     | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Pfizer Inc                                     | Pfizer Inc                                            | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |      1206 | NS      | $29438.46     | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                                | Bio-Techne Corp                                       | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |       686 | NS      | $34540.10     | 1.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Edgewise Therapeutics Inc                      | Edgewise Therapeutics Inc                             | CUSIP: 28036F105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       352 | NS      | $5772.80      | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| AC Immune SA                                   | AC Immune SA                                          | CUSIP: 000000000<br>LEI: 967600VLQ0ZC2HSOG765 | Long             | EC               | CORP              | CH        |       525 | NS      | $908.25       | 0.03%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                                         | UCB SA                                                | CUSIP: 000000000<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |       336 | NS      | $61601.94     | 2.11%             |  |  |  | No            |                  2 | On Loan: No      |
| Edwards Lifesciences Corp                      | Edwards Lifesciences Corp                             | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |      1101 | NS      | $83114.49     | 2.85%             |  |  |  | No            |                  1 | On Loan: No      |
| QIAGEN NV                                      | QIAGEN NV                                             | CUSIP: 000000000<br>LEI: 54930036WK3GMCN17Z57 | Long             | EC               | CORP              | NL        |       662 | NS      | $28300.50     | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                                      | Argenx SE                                             | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |       172 | NS      | $110964.08    | 3.81%             |  |  |  | No            |                  1 | On Loan: —       |
| Cencora Inc                                    | Cencora Inc                                           | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |       255 | NS      | $74630.85     | 2.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                                     | Insmed Inc                                            | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |       333 | NS      | $23976.00     | 0.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcus Biosciences Inc                          | Arcus Biosciences Inc                                 | CUSIP: 03969F109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       272 | NS      | $2380.00      | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Voyager Therapeutics Inc                       | Voyager Therapeutics Inc                              | CUSIP: 92915B106<br>LEI: 54930082S4XVR0ZWCC74 | Long             | EC               | CORP              | US        |       585 | NS      | $2082.60      | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Vir Biotechnology Inc                          | Vir Biotechnology Inc                                 | CUSIP: 92764N102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       340 | NS      | $2080.80      | 0.07%             |  |  |  | No            |                  1 | On Loan: —       |
| Arvinas Inc                                    | Arvinas Inc                                           | CUSIP: 04335A105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       390 | NS      | $3751.80      | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| BeiGene Ltd                                    | BeiGene Ltd                                           | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | KY        |       170 | NS      | $44167.70     | 1.52%             |  |  |  | No            |                  1 | On Loan: —       |
| Natera Inc                                     | Natera Inc                                            | CUSIP: 632307104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       336 | NS      | $50712.48     | 1.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc                     | Neurocrine Biosciences Inc                            | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |       353 | NS      | $38014.57     | 1.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Exelixis Inc                                   | Exelixis Inc                                          | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |      1234 | NS      | $48311.10     | 1.66%             |  |  |  | No            |                  1 | On Loan: No      |
| McKesson Corp                                  | McKesson Corp                                         | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |       100 | NS      | $71279.00     | 2.45%             |  |  |  | No            |                  1 | On Loan: No      |
| BLACKROCK CASH FUNDS TREASURY SL AGENCY SHARES | BlackRock Cash Funds: Treasury, SL Agency Shares      | CUSIP: 066922477<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |    170000 | NS      | $170000.00    | 5.83%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                                   | Danaher Corp                                          | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |       143 | NS      | $28504.19     | 0.98%             |  |  |  | No            |                  1 | On Loan: No      |
| Summit Therapeutics Inc                        | Summit Therapeutics Inc                               | CUSIP: 86627T108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |        90 | NS      | $2170.80      | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |
| REGENXBIO Inc                                  | REGENXBIO Inc                                         | CUSIP: 75901B107<br>LEI: 549300EOES47LATSET33 | Long             | EC               | CORP              | US        |       306 | NS      | $2940.66      | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Glaukos Corp                                   | Glaukos Corp                                          | CUSIP: 377322102<br>LEI: 5299004JA1LHE21M6T14 | Long             | EC               | CORP              | US        |       127 | NS      | $11969.75     | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                                    | Novartis AG                                           | CUSIP: 000000000<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |       255 | NS      | $29084.58     | 1.00%             |  |  |  | No            |                  2 | On Loan: No      |
| Teva Pharmaceutical Industries Ltd             | Teva Pharmaceutical Industries Ltd                    | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |       465 | NS      | $7212.15      | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Metsera Inc                                    | Metsera Inc                                           | CUSIP: 59267L107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       321 | NS      | $7739.31      | 0.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Alkermes PLC                                   | Alkermes PLC                                          | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | IE        |       522 | NS      | $15017.94     | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Quest Diagnostics Inc                          | Quest Diagnostics Inc                                 | CUSIP: 74834L100<br>LEI: 8MCWUBXQ0WE04KMXBX50 | Long             | EC               | CORP              | US        |       125 | NS      | $22277.50     | 0.76%             |  |  |  | No            |                  1 | On Loan: No      |
| STERIS PLC                                     | STERIS PLC                                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | IE        |        20 | NS      | $4494.80      | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| West Pharmaceutical Services Inc               | West Pharmaceutical Services Inc                      | CUSIP: 955306105<br>LEI: 5493007NKRGM1RJQ1P16 | Long             | EC               | CORP              | US        |       136 | NS      | $28735.44     | 0.99%             |  |  |  | No            |                  1 | On Loan: No      |
| PTC Therapeutics Inc                           | PTC Therapeutics Inc                                  | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |       426 | NS      | $21231.84     | 0.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Waters Corp                                    | Waters Corp                                           | CUSIP: 941848103<br>LEI: 5T547R1474YC9HOD8Q74 | Long             | EC               | CORP              | US        |        45 | NS      | $15647.85     | 0.54%             |  |  |  | No            |                  1 | On Loan: No      |
| 4D Molecular Therapeutics Inc                  | 4D Molecular Therapeutics Inc                         | CUSIP: 35104E100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       177 | NS      | $596.49       | 0.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Roivant Sciences Ltd                           | Roivant Sciences Ltd                                  | CUSIP: 000000000<br>LEI: 549300DL466NY5J6U724 | Long             | EC               | CORP              | BM        |      1578 | NS      | $18336.36     | 0.63%             |  |  |  | No            |                  1 | On Loan: —       |
| Hologic Inc                                    | Hologic Inc                                           | CUSIP: 436440101<br>LEI: 549300DYP6F5ZJL0LB74 | Long             | EC               | CORP              | US        |       554 | NS      | $32242.80     | 1.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co                        | Bristol-Myers Squibb Co                               | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |      1087 | NS      | $54567.40     | 1.87%             |  |  |  | No            |                  1 | On Loan: No      |
| Allogene Therapeutics Inc                      | Allogene Therapeutics Inc                             | CUSIP: 019770106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1179 | NS      | $1980.72      | 0.07%             |  |  |  | No            |                  1 | On Loan: —       |
| Gilead Sciences Inc                            | Gilead Sciences Inc                                   | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |       644 | NS      | $68611.76     | 2.35%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-05-30

**Name of Applicant:** BlackRock ETF Trust

**Signature:** Chuck Pulsfort

**Name of Signer:** Chuck Pulsfort

**Title:** Assistant Treasurer